ASSOCIATION FOR PRESCRIPTION PSYCHEDELICS Mission Statement join us
To educate and advocate for the development and accessibility of safe and effective prescription psychedelic medicines for patients.
Doctors visit

Guiding Principles

Leadership

Serve as the trusted and recognized industry voice – at the national and state levels – on prescription psychedelic medicine and its integration into the healthcare system. Demonstrate the importance of government-sponsored research, public-private partnerships, patient centricity, and healthcare infrastructure development to support the foundation of this innovative area of medicine.

Education

Promote accurate information about prescription psychedelic medicine by educating policymakers, regulators, and other key stakeholders about psychedelics and entactogens/empathogens and the associated medical conditions each compound may be able to treat.

Patient Centricity

Prioritize ethical standards in research, manufacturing, access, and administration of prescription psychedelic medicine to ensure patient safety and well-being. Support patient centered medication treatment guidelines that prioritize the needs and experiences of patients and champion the adoption of FDA-approved prescription psychedelics provided by licensed health care providers.

Advocacy

Advance responsible legislative and regulatory policies that drive innovation, increase funding for research, and enhance access and coverage for prescription psychedelic medicine. Advocate for the use of prescription psychedelic medication based on rigorous scientific research, clinical trials, and empirical evidence, while supporting ongoing research to expand the field of knowledge.

Collaboration

Foster collaboration among industry, academic researchers, healthcare professionals, policy makers and patients to advance understanding and integration of prescription psychedelic medicine into the healthcare system.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Scientific Advisors

Peter Hendricks, Ph.D.
Professor and Heersink Endowed Chair of Psychiatry
University of Alabama at Birmingham
George Greer, M.D.
President, Co-Founder
Heffter Research Institute
Paul R. Hutson, Pharm.D., M.S.
Director of the UW Madison Transdisciplinary Center for Research in Psychoactive Substances
University of Wisconsin
Matthew W. Johnson, Ph.D.
Senior Researcher
Sheppard Pratt
Brian Barnett, M.D.
Clinical Director, Cleveland Clinic Psychiatric Treatment Resistance Program
Cleveland Clinic
Jennifer Jones, M.D.
Assistant Professor of Psychiatry and Behavioral Sciences and Director of MUSC Centerspace
Medical University of South Carolina
Sandeep Nayak, M.D.
Assistant Professor of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
Robin Carhart-Harris, Ph.D.
Ralph Metzner Distinguished Professor of Neurology, Psychiatry and Behavioral Sciences
University of California San Francisco

Member Companies

Patient Advocacy Organization Supporters